文献速递血栓与止血

可实现皮下给药的重组凝血因子IX融合蛋白的特征分析

Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.
PubMed 文献 · J Thromb Haemost · 2024-07-15

本研究在体外和小鼠模型中表征两种重组凝血因子IX白蛋白融合蛋白变异体R338L与R338L/E410K,并与已上市野生型rIX-FP比较。R338L-FP在静脉和皮下给药后活性暴露更高,在尾部剪出血模型中减少出血时间与失血量疗效与野生型相当,所需蛋白量约低4倍,作者认为其是皮下给药的有前景候选。

要点

  • 两种rIX-FP变异体体外比活性较rIX(WT)-FP提高4至5倍。
  • rIX(R338L)-FP静脉和皮下给药后FIX活性暴露高于rIX(WT)-FP和rIX(R338L/E410K)-FP。
  • 尾部剪出血模型中rIX(R338L)-FP疗效与rIX(WT)-FP相当,所需蛋白量约低4倍。

核心结论

  • rIX(R338L)-FP被证明是皮下给药的有前景候选,具有提高的比活性、更高的活性暴露,并提示在较低蛋白剂量下即有疗效。

研究设计与样本

  • 体外表征两种rIX-FP变异体R338L(Padua变异体)和R338L/E410K,并在FIX缺陷小鼠中评估静脉和皮下给药后FIX抗原与活性水平的药代动力学。
  • 在尾部剪出血模型中测试最有前景变异体在静脉和皮下给药(按活性给药)的疗效,以已上市野生型rIX-FP产品为对照。

主要发现

  • 两种rIX-FP变异体体外比活性较rIX(WT)-FP提高4至5倍,FXIa介导的活化以rIX(WT)-FP和rIX(R338L)-FP最快。
  • rIX(R338L)-FP静脉和皮下给药后FIX活性暴露高于rIX(WT)-FP和rIX(R338L/E410K)-FP。
  • 尾部剪出血模型中rIX(R338L)-FP减少出血时间和失血量的疗效与rIX(WT)-FP相当,所需蛋白量约低4倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The X-linked bleeding disorder hemophilia B, caused by mutation(s) in the coagulation factor (F)IX gene, leads to partial or total loss of its function, requiring lifelong FIX replacement therapy. Although new recombinant FIX (rIX) therapeutics like albumin fusion proteins (rIX-FP) enable longer plasma half-life and thus less frequent administration, the complexity of intravenous (i.v.) injection remains. OBJECTIVES: The study aimed to characterize rIX-FP variants with anticipated enhanced specific activity, which would leverage rIX-FP's superior pharmacokinetic profile with beneficial characteristics for subcutaneous (s.c.) administration. METHODS: Two rIX-FP variants, R338L ("Padua variant") and R338L/E410K, were characterized in vitro. Pharmacokinetic profiles of FIX antigen and activity levels were evaluated in FIX-deficient mice after i.v. and s.c. administration of these variants (dosing based on antigen levels). The efficacy of the most promising variant was tested after i.v. and s.c. administration (dosing based on activity) in a tail clip bleeding model. A marketed wild-type (WT) rIX-FP product served as the comparator. RESULTS: Both rIX-FP variants showed a 4- to 5-fold increase in specific activity in vitro compared with rIX(WT)-FP, while FXIa-mediated activation was the fastest for rIX(WT)-FP and rIX(R338L)-FP. Compared with rIX(WT)-FP and rIX(R338L/E410K)-FP, rIX(R338L)-FP exhibited higher FIX activity exposure after i.v. and s.c. administration and demonstrated comparable efficacy with rIX(WT)-FP in reducing bleeding time and blood loss in FIX-deficient mice requiring ∼4 times lower protein amount. CONCLUSION: rIX(R338L)-FP was shown to be a promising candidate for s.c. administration, exhibiting increased specific activity combined with higher activity-based exposure and indicating efficacy at a lower protein dose.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Schön K, Pestel S, Riedesel J, et al. Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration. J Thromb Haemost. 2024. PMID: 39019440. doi:10.1016/j.jtha.2024.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。